News InflaRx flatlines after skin disease drug flops in midstage trial Phil Taylor InflaRX, skin cancer 0 Comment Shares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug Share X InflaRx flatlines after skin disease drug flops in midstage trial https://pharmaphorum.com/news/inflarx-flatlines-skin-disease-drug-midstage-trial/
